Is there a role for HIPEC in ovarian cancer?

Abstract

Hyperthermic intraperitoneal chemotherapy (HIPEC) is promoted by some as a standard treatment for peritoneal carcinomatosis of epithelial ovarian cancer (EOC) and other tumor entities, despite lack of robust data supporting this. Publicly available evidence addressing the value of HIPEC in EOC is rather inconclusive, revealing contradictory and inconsistent results while some studies even report harm to the patients from a higher morbidity. On this ground, we cannot recommend the implementation and use of HIPEC outside of a randomized clinical trial setting.

• Authors: Philipp Harter, Andreas du Bois, Jalid Sehouli, Sven Mahner, Ignace Vergote, Luis Chiva, Antonio Gonzalez-Martin, Christina Fotopoulou
• Journal: Archives of gynecology and obstetrics (Arch Gynecol Obstet) Vol. 298 Issue 5 Pg. 859-860 (11 2018) ISSN: 1432-0711 [Electronic] Germany
• PMID: 30232581 (Publication Type: News)

Topics

• Female
• Humans
• Hyperthermia, Induced (methods)
• Ovarian Neoplasms (drug therapy, pathology)
• Peritoneal Neoplasms (drug therapy, pathology)